XOMAP News and Press, XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock

2026-03-31 07:35:00 ET Co-authored with Hidden Opportunities You've had those days when you start early, jump straight into solving problems, putting out fires, and juggling deadlines, and before you know it, it's dark outside. It was no doubt a productive day; you got things do...

EMERYVILLE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A ...

2026-03-18 16:12:28 ET XOMA Royalty Corporation (XOMA) Q4 2025 Earnings Call March 18, 2026 8:00 AM EDT... Read the full article on Seeking Alpha For further details see: XOMA Royalty Corporation (XOMA) Q4 2025 Earnings Call Transcript

Portfolio receipts : • Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increased 9% with royalties up 68% versus full year 2024 Business development : Added 22 assets to portfo...

EMERYVILLE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty announced today it will report fourth quarter and full year 2025 financial results on Wednesday, March 18. The Company will host a webcast on March 18, 2026, at 8:00 am Eastern Time...

2026-02-10 20:45:48 ET ... Read the full article on Seeking Alpha For further details see: XOMA Royalty: Preferreds Still Offer Compelling Income Despite Call Risk

EMERYVILLE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, tod...

EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from his position with XOMA Royalty to pursue other professional opportunities.  ...

– Takeda regains a majority of XOMA Royalty’s royalty interest in mezagitamab (TAK-079) – – XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine development-stage assets held within Takeda’s externalized a...

EMERYVILLE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA), the biotech royalty aggregator, today announced it has successfully completed its previously announced acquisition of the entire issued and to be issued share capital of M...